Elanco Raises Full-Year Outlook on Strong Q2, Led by Pet Health and Innovation

summarizeSummary

Elanco reported Q2 2026 revenue of $1.37B (+10% YoY) and raised full-year guidance for revenue, Adjusted EBITDA, and Adjusted EPS, driven by strong demand for new pet health products and margin expansion.

check_boxKey Events · Earnings and Guidance · ELAN

• Q2 Revenue and Earnings Beat

  Revenue of $1,368M grew 10% YoY (8% organic constant currency), with Pet Health up 12% and Farm Animal up 9%. Adjusted EPS of $0.34 beat expectations, up 31% YoY.

• Full-Year Guidance Raised

  Revenue guidance raised to $5.09B-$5.14B (from $5.01B-$5.085B), Adjusted EBITDA to $1.01B-$1.035B (from $975M-$1.005B), and Adjusted EPS to $1.10-$1.16 (from $1.03-$1.09).

• Innovation Driving Growth

  Innovation revenue target raised to $1.25B. Zenrelia achieved blockbuster status, and Credelio Quattro accelerated market share gains, penetrating over 50% of U.S. clinics.

• Margin Expansion and Deleveraging

  Adjusted EBITDA margin expanded to 21.2% (from 19.2% a year ago). Net leverage ratio improved to 3.1x, with year-end target improved to approximately 3.0x, ahead of schedule.

auto_awesomeAnalysis · ELAN · Life Sciences

Elanco delivered a strong Q2 with 10% revenue growth and raised its full-year guidance across all key metrics. The beat-and-raise quarter was driven by new product launches—Zenrelia and Credelio Quattro—which are gaining market share rapidly. Adjusted EBITDA margin expanded faster than expected, and the net leverage ratio improved to 3.1x, putting the company within reach of its sub-3x target. The raised innovation revenue target to $1.25 billion signals confidence in the pipeline. This is a clear positive signal for the investment thesis, though the stock's reaction will depend on whether the market had already priced in the momentum.